CLAIMS

1. A composition comprising a viral vector comprising nucleic acid having a polynucleotide sequence encoding at least one epitope of the varicella-zoster virus (VZV) Gly E antigen, in which the viral vector is an adenoviral vector.

2. A composition according to Claim 1, in which the at least one epitope comprises at least one CD4 T cell epitope and at least one CD8 T cell epitope.

3. A composition according to Claim 1 or 2, in which the adenoviral vector is of human or simian origin.

4. A composition according to Claim 1, 2 or 3, in which the adenoviral vector is ChAdOx 1 or ChAdOx 2.

5. A composition according to any preceding claim, in which the composition is adjuvant-free.

6. A composition according to any preceding claim, in which the Gly E antigen has the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, suitably SEQ ID NO: 2.

7. A composition according to any preceding claim, in which the polynucleotide sequence comprises the sequence of SEQ ID NO: 3 or SEQ ID NO: 4, suitably SEQ ID NO: 4.

8. A composition according to any preceding claim, in which the polynucleotide sequence further comprises the sequence of the bgh polyadenylation signal SEQ ID NO: 6.

9. A composition according to any preceding claim, in which the polynucleotide sequence encoding at least one epitope of the varicella-zoster virus (VZV) Gly E antigen is operably connected to the long CMV promoter, suitably the long CMV promoter has the nucleotide sequence of SEQ ID NO: 7.

10. A composition according to any preceding claim, in which the viral vector sequence is as in ECACC accession number 12052403 (ChAdOx1), or in which the viral vector sequence is as in SEQ ID NO: 5 (ChAdOx2).

11. A composition according to any preceding claim, in which administration of a single dose of the composition to a mammalian subject induces protective immunity in the subject.

12. A composition according to any preceding claim for induction of an immune response against VZV, preferably in which a single dose of the composition is administered, preferably in which the composition is administered once.

13. A composition according to any preceding claim for induction of an immune response against VZV, in which the composition is administered once per 5 years, more suitably once per year.

14. A composition according to any preceding claim for preventing VZV infection, or for prevention of shingles, preferably in which a single dose of the composition is administered, preferably in which the composition is administered once.

15. A composition according to any preceding claim for treatment or prevention of chickenpox.